Please login to the form below

Not currently logged in

Therachon appoints new chief medical officer

Dr Maarten Kraan joins the company from AstraZeneca

Dr Maarten KraanBasel, Switzerland-based biotech company Therachon has appointed Dr Maarten Kraan as its new chief medical officer in a role that will see him focus on the clinical development of TA-46 - Therachon’s leading drug in development for achondroplasia.

Kraan has held numerous roles such as vice president, immunosciences at Bristol-Myers Squibb, vice president, head of clinical research and experimental development at Roche, and most recently as head of innovative medicines respiratory and inflammation at AstraZeneca.

Luca Santarelli, chief medical officer at Therachon, said: “Dr Kraan’s wealth of translational and drug development expertise is critical during this exciting time in our company’s growth. He will play a key role in guiding TA-46 from discovery into clinical development and helping us fulfill our mission of developing medicines for rare, genetic diseases.”

In addition to his new role Dr Kraan will continue to serve as an adjunct professor at Goteborg University in Sweden.

27th March 2017

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...